First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Subjects

Subjects :

INVESTIGATIONAL drugs
ACADEMIC medical centers
ANTINEOPLASTIC agents
DOSE-response relationship in biochemistry
LONGITUDINAL method
LUNG cancer
MEDICAL cooperation
OVARIAN tumors
RESEARCH
TREATMENT effectiveness
DESCRIPTIVE statistics
PHARMACODYNAMICS
THERAPEUTICS

Details

Language :

English

ISSN :

01676997

Volume :

33

Issue :

6

Database :

Complementary Index

Journal :

Investigational New Drugs

Publication Type :

Academic Journal

Accession number :

111005234

Full Text :

https://doi.org/10.1007/s10637-015-0299-2